JP2002518011A5 - - Google Patents

Download PDF

Info

Publication number
JP2002518011A5
JP2002518011A5 JP2000554853A JP2000554853A JP2002518011A5 JP 2002518011 A5 JP2002518011 A5 JP 2002518011A5 JP 2000554853 A JP2000554853 A JP 2000554853A JP 2000554853 A JP2000554853 A JP 2000554853A JP 2002518011 A5 JP2002518011 A5 JP 2002518011A5
Authority
JP
Japan
Prior art keywords
bpi
analog
host cell
deleted
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000554853A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002518011A (ja
Filing date
Publication date
Priority claimed from US09/099,725 external-priority patent/US6013631A/en
Application filed filed Critical
Publication of JP2002518011A publication Critical patent/JP2002518011A/ja
Publication of JP2002518011A5 publication Critical patent/JP2002518011A5/ja
Pending legal-status Critical Current

Links

JP2000554853A 1998-06-19 1999-06-18 殺菌性/透過性増加タンパク質(bpi)欠失アナログ Pending JP2002518011A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/099,725 US6013631A (en) 1998-06-19 1998-06-19 Bactericidal/permeability-increasing protein (BPI) deletion analogs
US09/099,725 1998-06-19
PCT/US1999/013860 WO1999066044A1 (en) 1998-06-19 1999-06-18 Bactericidal/permeability-increasing protein (bpi) deletion analogs

Publications (2)

Publication Number Publication Date
JP2002518011A JP2002518011A (ja) 2002-06-25
JP2002518011A5 true JP2002518011A5 (cg-RX-API-DMAC7.html) 2006-06-29

Family

ID=22276330

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000554853A Pending JP2002518011A (ja) 1998-06-19 1999-06-18 殺菌性/透過性増加タンパク質(bpi)欠失アナログ

Country Status (9)

Country Link
US (4) US6013631A (cg-RX-API-DMAC7.html)
EP (1) EP1086230A1 (cg-RX-API-DMAC7.html)
JP (1) JP2002518011A (cg-RX-API-DMAC7.html)
CN (1) CN1273598C (cg-RX-API-DMAC7.html)
AU (1) AU755624B2 (cg-RX-API-DMAC7.html)
CA (1) CA2331880A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA00011398A (cg-RX-API-DMAC7.html)
NZ (1) NZ508816A (cg-RX-API-DMAC7.html)
WO (1) WO1999066044A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
WO2000071149A2 (en) * 1999-05-24 2000-11-30 Xoma (Us) Llc Therapeutic uses of bpi protein products in humans with otitis media with effusion
JP2004517865A (ja) * 2000-12-01 2004-06-17 ゾーマ テクノロジー リミテッド Bpiタンパク質産物またはbpiインヒビターを使用する、周皮細胞増殖の調節
ATE496134T1 (de) 2002-03-29 2011-02-15 Xoma Technology Ltd Multigene vectoren und methoden für eine erhöhte expression von rekombinanten polypeptiden
AU2004216298B2 (en) * 2003-02-28 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
EP1891207A2 (en) * 2005-06-03 2008-02-27 Biovitrum AB Process for cultivating animal cells comprising the feeding of plant-derived peptones
EP1741440A1 (en) 2005-07-08 2007-01-10 Mellitus S.L. Use of BPI protein for the treatment of disorders of the metabolism and cardiovascular disorders
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
CA2680792A1 (en) * 2007-03-15 2008-09-18 Biogen Idec Ma Inc. Treatment of autoimmune disorders
EP2694084B1 (en) 2011-04-05 2016-03-23 Dana-Farber Cancer Institute, Inc. Bpi and its congeners as radiation mitigators and radiation protectors
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
KR102270048B1 (ko) * 2020-07-10 2021-06-28 주식회사 녹십자 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법
CN115947868B (zh) * 2022-09-28 2026-05-12 安君(北京)基因科技有限责任公司 Cxcl-bpi融合蛋白及其用途

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5576292A (en) * 1987-08-11 1996-11-19 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US5770694A (en) * 1990-08-13 1998-06-23 Incyte Pharmaceuticals, Inc. Genetically engineered BPI variant proteins
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
WO1992009621A1 (en) * 1990-12-03 1992-06-11 New York University Biologically active bactericidal/permeability-increasing protein fragments
EP0605653A4 (en) * 1991-09-26 1995-03-15 Incyte Pharma Inc NEW LIPOSACCHARID BINDING PROTEIN (LBP).
WO1993023434A2 (en) * 1992-05-19 1993-11-25 Xoma Corporation Bpi-immunoglobulin fusion proteins
US5439807A (en) * 1992-05-19 1995-08-08 Xoma Corporation Methods for the preparation of endotoxin-binding proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US5488034A (en) * 1993-02-02 1996-01-30 Xoma Corporation Pharmaceutical composition comprising BPI proteins
WO1994019323A1 (en) 1993-02-18 1994-09-01 Merck Sharp & Dohme Limited Azacyclic compounds, compositions containing them and their use as tachykinin antagonists
US5733872A (en) * 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
CA2157927C (en) * 1993-03-12 1999-03-30 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein produc ts
DK0690872T3 (da) * 1993-03-12 1999-05-10 Xoma Corp Biologisk aktive peptider fra funktionelle domæner af baktericidt/permeabilitetsforøgende protein og anvendelser deraf
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
ES2119185T3 (es) * 1993-03-12 1998-10-01 Xoma Corp Tratamiento de enfermedades micobacterianas por administracion de productos de la proteina bactericida/que aumenta la permeabilidad.
AU6522794A (en) * 1993-03-22 1994-10-11 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein and lipopolysaccharide binding protein levels and ratios thereof in diagnosis
AU6942994A (en) * 1993-04-30 1994-11-21 Incyte Pharmaceuticals, Inc. Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof
US5731415A (en) * 1993-06-17 1998-03-24 Xoma Corporation Lipopolysaccharide binding protein derivatives
EP0726944B1 (en) * 1993-07-02 2002-12-18 Incyte Pharmaceuticals, Inc. Glycosylated and non-glycosylated bactericidal/permeability increasing proteins, and methods for producing same
AU7330994A (en) * 1993-07-14 1995-02-13 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
US5770561A (en) * 1993-07-14 1998-06-23 Xoma Corporation Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
US5466580A (en) * 1993-09-22 1995-11-14 Xoma Corporation Method for quantifying BPI in body fluids
DK0759774T3 (da) * 1993-09-22 2002-10-07 Xoma Technology Ltd Fremgangsmåde til behandling af gram-negativ bakteriel infektion ved indgivelse af baktericidt/permeabilitet-forøgende (BPI) proteinprodukt og antibiotikum
CN1133634A (zh) * 1993-09-22 1996-10-16 爱克斯欧玛公司 定量体液中的bpi的方法
ZA947783B (en) * 1993-10-15 1996-05-05 Xoma Corp Method of treating depressed reticuloendothelial system function
CA2181164C (en) * 1994-01-14 2008-01-08 Arnold Horwitz Anti-gram-positive bacterial methods and materials
WO1995019179A1 (en) * 1994-01-14 1995-07-20 Xoma Corporation Anti-fungal methods and materials
US5484705A (en) * 1994-01-24 1996-01-16 Xoma Corporation Method for quantifying lipopolysaccharide binding protein
US5643875A (en) * 1994-01-24 1997-07-01 Friedmann; Nadav Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5786324A (en) * 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5578568A (en) * 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
US5532216A (en) * 1994-06-24 1996-07-02 Incyte Pharmaceuticals, Inc. Neutralization of non-lipopolysaccharide compounds by bactericidal/permeability-increasing protein
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
DE69532302D1 (de) * 1994-09-15 2004-01-22 Xoma Technology Ltd Peptide gegen pilzen
US5912228A (en) * 1995-01-13 1999-06-15 Xoma Corporation Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
WO1997004008A1 (en) * 1995-07-20 1997-02-06 Xoma Corporation Anti-fungal peptides
US5686414A (en) * 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation
CA2235626C (en) * 1995-11-14 2002-01-01 Xoma Corporation Bactericidal permeability increasing protein (bpi) for treating conditions associated with corneal injury
AU735058B2 (en) * 1996-05-10 2001-06-28 Xoma Corporation Therapeutic uses of BPI protein products for human meningococcemia
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
ATE234111T1 (de) * 1996-05-23 2003-03-15 Xoma Technology Ltd Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
EP1304118A3 (en) * 1996-11-01 2004-01-14 XOMA Technology Ltd. Therapeutic uses and formulations for BPI protein products.
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs

Similar Documents

Publication Publication Date Title
JP2003530839A5 (cg-RX-API-DMAC7.html)
ES2426420T3 (es) Péptidos de queratina bioactivos
JP2004501618A5 (cg-RX-API-DMAC7.html)
JPH10502360A (ja) ヒトインターロイキン4のアンタゴニストもしくは部分的アゴニストとして用いられる新規hIL−4突然変異蛋白質
EP1310558A3 (en) Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same
CA2230885A1 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
CZ350296A3 (en) Polypetides and pharmaceutical compositions containing thereof
EP1548028A4 (en) SUBSTITUTED WT1 PEPTIDES
MY123371A (en) Protein for blocking platelet adhesion
ES2279510T3 (es) Generacion de insulina humana.
HRP20170755T1 (hr) Rekombinantni proteini elastaze i postupci proizvodnje i uporabe istih
NO20013608L (no) DNA-klon for human vevsfaktorinhibitor
DK170346B1 (da) Granulocyt-makrofag-"Colony Stimulating"-faktor(CSF)-proteiner, fremgangsmåde til fremstilling deraf, ekspressionsvektor og E.coli-celle til brug ved denne fremgangsmåde samt anvendelse af disse proteiner
WO2004022003A3 (en) Materials and methods for treatment of allergic diseases
HU0000992D0 (en) Genetically engineered cell culture adapted infections bursal diseases virus (ibdv)mutants
KR880009125A (ko) 재조합 숙주에 의해 제조되는 췌장분비 트립신 억제제 및 그의 변이체, 그의 방법, 표현벡터 및 재조합 숙주 및 그의 제약상 용도
DE68926679D1 (de) Physiologisch aktives polypeptid, rekombinantes plasmid, rekombinante mikrobielle zellen, medizinisches präparat sowie verfahren zur gewinnung des gereinigten polypeptids
JP2001029093A (ja) インターロイキン−1インヒビター
JP2005519591A (ja) 毛包成長
JP2005053929A (ja) 肺胞界面活性タンパク質
NZ508816A (en) Bactericidal/permeability-increasing protein (BPI) deletion analogs
EP1209226A3 (en) Maturation of dendritic cells by recombinant heat shock protein 70 (hsp70)
CA2011008C (en) Egf variants and pharmaceutical use thereof
JPWO2016084935A1 (ja) Iii型コラーゲン産生促進剤
CA2423616A1 (en) Chemokine mutants in the treatment of multiple sclerosis